Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | GCGR | P47871 | 8/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17975734 | 0.82 | GCGR (0.53) | GCGRKIT | |
| SCHEMBL2221425 | 0.82 | PTGS2 (0.37) | JAK1GCGRPTGS2KITHMGCR | |
| SCHEMBL14953476 | 0.82 | JAK1 (0.36) | JAK1GCGRPTGS2KITHMGCR | |
| SCHEMBL4773885 | 0.82 | GCGR (0.41) | GCGRKIT | |
| SCHEMBL3264910 | 0.82 | GCGR (0.41) | GCGRKIT | |
| SCHEMBL2306437 | 0.81 | JAK1 (0.38) | JAK1GCGRPTGS2KITHMGCR | |
| SCHEMBL15310067 | 0.80 | GCGR (0.40) | GCGR | |
| SCHEMBL15139859 | 0.80 | GCGR (0.39) | JAK1GCGRKIT | |
| Bromide SCHEMBL4449437 | 0.78 | GCGR (0.41) | GCGR | |
| Bromide SCHEMBL426278 | 0.78 | AKT1 (0.52) | PTGS2HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376397-B2 | Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof | LEK PHARMACEUTICALS D.D. (SI) | 2016-06-28 | — | — | US | disclosed |
| EP-2024341-B1 | NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | MSN LAB PRIVATE LTD (IN) | 2015-12-02 | — | — | EP | disclosed |
| US-20150141449-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2015-05-21 | — | — | US | disclosed |
| EP-2391609-B1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS (SI) | 2015-01-28 | — | — | EP | disclosed |
| EP-2341054-B1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS (SI) | 2014-06-25 | — | — | EP | disclosed |
| EP-1937696-B1 | PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS | LEK PHARMACEUTICALS (SI) | 2013-05-22 | — | — | EP | disclosed |
| US-8269001-B2 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2012-09-18 | — | — | US | disclosed |
| US-20120022091-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2012-01-26 | — | — | US | disclosed |
| EP-2341054-A1 | Process for the synthesis of HMG-CoA reductase inhibitors | LEK Pharmaceuticals d.d. (SI) | 2011-07-06 | — | — | EP | disclosed |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141449-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, FDPS, SIRT5 | JAK1 3693/4885GCGR 3607/4885PTGS2 2512/4885 |
| US-20080300406-A1 | Process for the Synthesis of Hmg-Coa Reductase Inhibitors | HMGCR, COASY, LSS | JAK1 4455/4885GCGR 1741/4885PTGS2 291/4885 |
| US-20120022091-A1 | KEY INTERMEDIATES FOR THE SYNTHESIS OF ROSUVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | HMGCR, FDPS, SIRT5 | JAK1 3693/4885GCGR 3607/4885PTGS2 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.